证券代码：002022 证券简称：科华生物 公告编号：2024-050 债券代码：128124 债券简称：科华转债 具体详见公司于同日在《证券时报》、《中国证券报》、《上海证券报》及巨潮 资讯网（http://www.cninfo.com.cn）披露的《2024 年第一季度报告》（公告编 号：2024-051）。 表决结果：同意3票，反对0票，弃权0票。 一、监事会会议召开情况 上海科华生物工程股份有限公司（以下简称"公司"）第十届监事会第三次 会议（以下简称"本次会议"或"会议"）通知于2024年4月23日以邮件方式送达 各位监事，会议于2024年4月26日以通讯表决方式召开。本次会议应出席监事3人， 实际出席监事3人。本次会议由监事会主席易超先生主持，会议的召开符合《中 华人民共和国公司法》、《上海科华生物工程股份有限公司章程》和《上海科华生 物工程股份有限公司监事会议事规则》的有关规定。 二、监事会会议审议情况 （一）审议通过《关于<2024 年第一季度报告>的议案》 经审议，监事会认为：公司董事会编制和审核《2024 年第一季度报告》的程 序符合相关法律、行政法规的规定，报告内容真实、准确、完整地反映 ...

Financial Performance - The company's revenue for Q1 2024 was ¥443,303,887.87, a decrease of 46.79% compared to ¥833,147,693.69 in the same period last year[4] - The net profit attributable to shareholders was a loss of ¥28,821,454.12, representing a decline of 152.63% from a profit of ¥54,761,876.98 in the previous year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was a loss of ¥39,116,563.64, down 181.25% from ¥48,141,247.97 in the same period last year[4] - Total operating revenue for Q1 2024 was CNY 443.30 million, a decrease of 46.7% compared to CNY 833.15 million in the same period last year[16] - Net profit for Q1 2024 was a loss of CNY 21.68 million, compared to a profit of CNY 97.17 million in Q1 2023, representing a significant decline[16] - The company's gross profit margin for Q1 2024 was approximately -8.8%, compared to a positive margin in the previous year[16] - The total comprehensive income for Q1 2024 was a loss of CNY 30.73 million, compared to a gain of CNY 94.88 million in the same period last year[17] Cash Flow - The net cash flow from operating activities improved by 64.87%, with a net outflow of ¥143,612,182.50 compared to a net outflow of ¥408,749,260.06 in the previous year[4] - The company reported a 41.65% decrease in cash inflows from operating activities, primarily due to reduced revenue[7] - Total cash inflow from operating activities decreased to 451,797,344.65 CNY, down 41.6% from 774,276,915.10 CNY in the previous period[18] - Cash outflow from operating activities also decreased to 595,409,527.15 CNY, down 49.7% from 1,183,026,175.16 CNY in the previous period[18] - The net cash flow from investing activities is -23,238,121.25 CNY, an improvement from -63,984,603.83 CNY in the previous period[19] - Cash inflow from investing activities increased to 20,806,243.66 CNY, compared to 8,606,841.20 CNY in the previous period[19] - Cash outflow from investing activities decreased to 44,044,364.91 CNY, down 39.4% from 72,591,445.03 CNY in the previous period[19] - The net cash flow from financing activities is -73,761,312.78 CNY, an improvement from -168,610,926.62 CNY in the previous period[19] - Cash inflow from financing activities decreased to 22,755,097.32 CNY, down 33.2% from 34,056,225.09 CNY in the previous period[19] - The ending cash and cash equivalents balance is 1,376,357,042.59 CNY, down from 2,822,735,743.35 CNY in the previous period[19] - The company’s cash and cash equivalents decreased by 239,639,024.47 CNY during the current period[19] Assets and Liabilities - Total assets at the end of the reporting period were ¥6,620,133,223.48, a decrease of 2.76% from ¥6,807,739,866.34 at the end of the previous year[4] - The total current assets decreased to RMB 4,142,000,005.65 from RMB 4,316,244,225.33, indicating a decline of approximately 4.0%[14] - Non-current assets totaled RMB 2,478,133,217.83, down from RMB 2,491,495,641.01, showing a decrease of about 0.5%[14] - The company's total liabilities decreased to CNY 1.74 billion in Q1 2024 from CNY 1.82 billion in the previous year[15] - The total equity attributable to shareholders of the parent company was CNY 4.07 billion, down from CNY 4.17 billion year-over-year[15] - The company reported a decrease in accounts payable to CNY 301.65 million from CNY 332.14 million in the previous year[15] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 46,370[10] - The company repurchased a total of 8,575,800 shares, resulting in an increase in treasury stock by ¥69,778,700[7] - The company's repurchase account held 8,575,800 shares, accounting for 1.67% of the total share capital as of the report date[11] - The company completed the transfer of 5% of its shares from Zhuhai Baolian Investment Holdings to Xi'an Zhitong Benyi Enterprise Management Partnership at a price of RMB 20 per share[12] - Xi'an Zhitong became the controlling shareholder after acquiring 25,715,859 shares, which represents 10.64% of the voting rights[12] - The board of directors was restructured, with Xi'an Zhitong nominating 5 out of 9 members, thus gaining substantial control over the company[12] Research and Development - Research and development expenses for Q1 2024 were CNY 47.23 million, a decrease of 28.2% from CNY 65.81 million in the same quarter last year[16]

致：上海科华生物工程股份有限公司 北京市金杜（广州）律师事务所（以下简称本所）接受上海科华生物工程股份 有限公司（以下简称公司）的委托，根据《中华人民共和国公司法》（以下简称《公 司法》）、《中华人民共和国证券法》（以下简称《证券法》）、中国证券监督管理委员 会《上市公司股东大会规则》（2022 年修订）（以下简称《股东大会规则》）等中华 人民共和国境内（以下简称中国境内，为本法律意见书之目的，不包括中国香港特 别行政区、中国澳门特别行政区和中国台湾地区）现行有效的法律、行政法规、规 章和规范性文件和现行有效的公司章程有关的规定，指派本所律师出席了公司于 2024 年 4 月 19 日召开的 2023 年度股东大会（以下简称本次股东大会），并就本次 股东大会相关事项出具本法律意见书。 为出具本法律意见书，本所律师审查了公司提供的以下文件，包括但不限于： 1 1． 经公司 2024 年第一次临时股东大会审议通过的《上海科华生物工程股份 有限公司章程》（以下简称《公司章程》）； 2． 公司于 2024 年 3 月 23 日刊登于巨潮资讯网及深圳证券交易所网站的《上 海科华生物工程股份有限公司第十届董事会第二次会议 ...

| 证券代码：002022 | 证券简称：科华生物 | | --- | --- | | 债券代码：128124 | 公告编号：2024-048 债券简称：科华转债 | 上海科华生物工程股份有限公司 2023年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会不存在否决议案的情形。 2、本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开情况 1、召开时间： （1）现场会议时间：2024年4月19日（星期五）下午14:30 （2）网络投票时间：2024年4月19日 其中，通过深圳证券交易所交易系统进行网络投票的具体时间为2024年4月 19日的交易时间，即9:15-9:25，9:30-11:30和13:00-15:00；通过深圳证券交易 所互联网投票系统投票的具体时间为2024年4月19日9:15-15:00期间的任意时间。 4、主持人：董事长李明先生 5、召开方式：本次股东大会采用现场投票、网络投票相结合的方式召开 6、本次会议的召集、召开符合《中华人民共和国公司法》（以下简称"《公 司法》"）、《上市公 ...

| 证券代码：002022 | 证券简称：科华生物 公告编号：2024-047 | | --- | --- | | 债券代码：128124 | 债券简称：科华转债 | 上海科华生物工程股份有限公司 关于产品获得医疗器械注册证的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，上海科华生物工程股份有限公司（以下简称"公司"）收到国家药品 监督管理局颁发的《医疗器械注册证》（体外诊断试剂）。具体情况如下： | 序号 | 产品名称 | 注册证编号 | | | 注册证有效期 | | | | 适用范围/预期用途 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1 | 戊型肝炎病毒 IgM 抗体检测试剂盒 | 国械注准 | 2024 | 年 | 03 至 | 月 | 28 | 日 | 本产品用于体外定性检测 人血清或血浆中的戊型肝 | | | （化学发光法） | 20243400608 | 2029 | 年 | 03 | 月 | 27 | 日 | 炎病毒 IgM 抗体（Anti ...

| 证券代码：002022 | 证券简称：科华生物 | | | --- | --- | --- | | 债券代码：128124 | 债券简称：科华转债 | 公告编号：2024-045 | 上海科华生物工程股份有限公司 关于以集中竞价方式回购公司股份的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 上海科华生物工程股份有限公司（以下简称"公司"）于 2023 年 10 月 27 日召开 第九届董事会第四次会议，审议通过了《关于以集中竞价方式回购公司股份方案的议 案》，公司拟使用自有资金以集中竞价交易方式回购公司股份，用于股权激励或员工 持股计划。本次回购资金总额为不低于人民币 10,000 万元（含）且不超过人民币 20,000 万元（含）；本次回购股份的价格为不超过人民币 11 元/股（含）。具体回购股 份数量以回购期限届满或者回购股份实施完毕时实际回购的股份数量为准。回购股份 期限为自董事会审议通过回购股份方案之日起 12 个月内。具体详见公司于 2023 年 10 月 30 日披露的《关于以集中竞价方式回购公司股份方案的公告》（公告编号：2023 ...

| 证券代码：002022 | 证券简称：科华生物 | | --- | --- | | 债券代码：128124 | 公告编号：2024-046 债券简称：科华转债 | 上海科华生物工程股份有限公司 关于 2024 年第一季度可转债转股情况的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： | 证券代码：002022 | | | | | | | | | | 证券简称：科华生物 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 债券代码：128124 | | | | | | | | | | 债券简称：科华转债 | | 转股价格：人民币 | | 20.64 | | | 元/股 | | | | | | | 转股期限：2021 | 年 | 2 | 月 | 3 | 日至 | 2026 | 年 7 | 月 | 27 | 日 | 根据《深圳证券交易所股票上市规则》、《深圳证券交易所上市公司自律监管 指引第 15 号——可转换公司债券》的有关规定，上海科华生物工程股份有 ...

2024 年 3 月 20 日，公司召开 2024 年第一次临时股东大会，选举产生了公司第十届董事会全 体董事和第十届监事会非职工代表监事，并通过了修订《公司章程》等议案。同日，公司召开第十 1 根据公司发布的《上海科华生物工程股份有限公司详式权益变动报告书》，《表决权委托协议》项下委托权利的委托期限可由珠海保联 和西安致同协商一致终止，否则自协议生效之日起至如下情形发生之日（以孰早者为准）止：1）本协议生效之日起满 6 年之日；2）除 去委托股份数量，按任一方直接与间接持有的科华生物股份所对应的表决权占科华生物总表决权的比例计算，西安致同表决权比例超过 珠海保联达 10%（含本数），且西安致同基于其所持有的股份所对应的表决权，能够并已经实际取得科华生物实际控制权与实际控制地 位的当日，但前述珠海保联表决权比例因被强制执行或平仓而减少的，不得计算在内。 联合〔2024〕1810 号 联合资信评估股份有限公司关于上海科华生物工程股份有限公司控制权 发生变更及董事会、监事会完成提前换届选举等事项的关注公告 联合资信评估股份有限公司（以下简称"联合资信"）受上海科华生物工程股份有限公司（以 下简称"公司"）委托对其 ...

Company Overview - Shanghai Kehua Bio-engineering Co., Ltd. was established in 1981 and is the first IVD listed company on the Shenzhen Stock Exchange [2] - The company specializes in the R&D, production, and sales of in vitro diagnostic reagents and medical testing instruments, covering molecular diagnostics, biochemical diagnostics, immunodiagnostics, and point-of-care testing (POCT) [2][3] - Kehua Bio has approximately 850 domestic and international registrations/certifications for its products, making it one of the most comprehensive companies in the IVD industry [2] Market Presence - The company has a coverage rate of about 60% in tertiary hospitals and 40% in blood stations in China, with nearly 900 clients in disease control centers and thousands of long-term partnerships with domestic and international agents [3] - Products have been exported to over 100 countries and regions worldwide [3][4] Sales Strategy - The sales model combines "mainly distribution, supplemented by direct sales," leveraging a broad network of distributors and a professional marketing team [3] - The company collaborates with various imported brands to provide comprehensive IVD products and services [3] Product Development and Market Strategy - Kehua Bio is actively adjusting its product strategy to cover multiple methodologies, including biochemical, immunofluorescence, molecular, and mass spectrometry [3][4] - The company aims to establish local service teams in key overseas markets, enhancing its global presence and brand recognition [4][5] Share Buyback Program - The company announced a share buyback plan on October 30, 2023, with a total fund of no less than RMB 100 million and no more than RMB 200 million, at a price not exceeding RMB 11 per share [4] - As of February 29, 2024, the company had repurchased 7,357,900 shares, accounting for 1.43% of the total share capital, with a transaction amount of RMB 60,036,310.16 [4] Future Development and Challenges - The company plans to focus on the animal market, including economic and pet animals, with a comprehensive solution covering biochemical, immunological, molecular, and coagulation methodologies [5] - In response to industry competition and trends such as centralized procurement and domestic substitution, the company aims to enhance its market influence and expand its market share [5]

Financial Performance - The company reported a significant increase in revenue, achieving a total of 1.5 billion RMB, representing a year-over-year growth of 20%[15]. - The company's operating revenue for 2023 was ¥2,428,075,213.95, a decrease of 65.16% compared to ¥6,969,862,627.72 in 2022[22]. - The net profit attributable to shareholders for 2023 was -¥234,014,886.40, representing a decline of 124.09% from ¥970,845,080.02 in 2022[22]. - The basic earnings per share for 2023 was -¥0.4550, down 124.09% from ¥1.8878 in 2022[23]. - The total assets at the end of 2023 were ¥6,807,739,866.34, a decrease of 22.81% from ¥8,813,157,013.32 at the end of 2022[23]. - The net cash flow from operating activities for 2023 was -¥474,894,786.47, a decline of 122.05% compared to ¥2,153,632,187.55 in 2022[22]. - In 2023, the company's total revenue was approximately ¥2.43 billion, a decrease of 65.16% compared to ¥6.97 billion in 2022[63]. - The domestic revenue accounted for 85.30% of total revenue, amounting to ¥2.07 billion, down 67.16% from ¥6.31 billion in the previous year[63]. Market Expansion and Strategy - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share within the next two years[15]. - The company has outlined a future outlook projecting a revenue growth of 25% for the next fiscal year, driven by new product launches and market expansion strategies[15]. - The company is actively seeking opportunities in overseas markets to mitigate challenges posed by geopolitical conflicts and to find new growth points[39]. - The company aims to expand its home self-testing product market, focusing on respiratory, digestive, and reproductive health, integrating digital devices and software to create a personal health management ecosystem[103]. - The company is set to expand its international market presence, particularly in emerging markets, by tailoring technology, product design, channels, pricing, and services to local market characteristics[103]. Research and Development - Investment in R&D has increased by 30%, focusing on innovative diagnostic technologies and enhancing product offerings[15]. - The company has a strong focus on R&D, with significant investments in biochemistry, immunology, molecular diagnostics, and POCT[53]. - R&D investment amounted to ¥317,543,861.24 in 2023, a decrease of 2.82% from ¥326,744,992.52 in 2022, while the R&D investment as a percentage of operating revenue increased significantly to 13.08% from 4.69%[75]. - The company has developed high-sensitivity nucleic acid testing reagents for HBV, HCV, HIV-1, and HIV-2, enhancing its product portfolio in the molecular diagnostics sector[51]. - The company has established partnerships with three leading universities for collaborative research, enhancing innovation capabilities[141]. Product Development and Launches - The company has successfully launched a new line of immunodiagnostic products, contributing to a 5% increase in market share in the domestic market[15]. - The company has launched a portable four-channel real-time fluorescence quantitative PCR instrument, enhancing its product offerings in the pet and livestock markets[74]. - New product launches include a cutting-edge medical device expected to generate an additional 300 million RMB in revenue in 2024[141]. - The company has launched the Polaris series of biochemical luminescence platforms, which supports modular connections and meets the needs of various medical institutions[58]. - The company has developed multiple diagnostic kits, including the free light chain K and λ, which have been certified for market release, enhancing the competitiveness of its kidney function product line[73]. Governance and Management - The company has implemented a robust corporate governance structure, including a board of directors and specialized committees to ensure effective decision-making and compliance[114]. - The company maintains independence from its major shareholder, ensuring that significant decisions are made autonomously[116]. - The company appointed a new president, Mr. Li Ming, effective from April 3, 2023, following the resignation of Ms. Chen Chao from the position[128]. - The board of directors held a total of 12 meetings during the reporting period, with various resolutions disclosed in multiple financial news outlets[145]. - The company has established independent departments for various functions, including sales, R&D, and finance, ensuring no overlap with major shareholders' operations[121]. Financial Management and Investments - The company raised a total of RMB 738 million through the issuance of convertible bonds, with a net amount received of RMB 718.53 million after deducting issuance costs[92]. - The company has provided guarantees totaling CNY 10,000 million to its subsidiaries during the reporting period, with an actual occurrence of CNY 1,000 million[197]. - The company has entrusted financial management with a total amount of CNY 165,700 million, including CNY 120,700 million from self-owned funds and CNY 15,000 million from raised funds[199]. - The company has not engaged in any significant asset or equity acquisition transactions during the reporting period[186]. - The company has not reported any significant changes in cash asset management strategies[198]. Compliance and Risk Management - The company emphasizes the importance of compliance with industry regulations, as changes in regulatory policies could adversely affect its operations[106]. - The company has established a management system for hedging operations, ensuring compliance with operational norms and risk control measures[88]. - The company has implemented measures to monitor and control risks associated with foreign exchange hedging, including regular audits and compliance checks[88]. - The company has established a comprehensive quality management system, ensuring compliance with IVD industry regulations and enhancing customer satisfaction[55]. - The company has not reported any significant discrepancies between its governance practices and the regulations set forth by the China Securities Regulatory Commission[119]. Employee Engagement and Development - The company emphasizes employee rights and development, providing training and a supportive work environment[171]. - The company has a training system in place that includes onboarding for new employees and ongoing training for current staff to enhance overall capabilities[154]. - The company held its first employee representative meeting on June 19, 2023, and elected Ms. Chen Dunfang as the employee supervisor[129]. - The company has seen a 7.70% decrease in R&D personnel, with the total number dropping from 675 in 2022 to 623 in 2023, while the proportion of R&D staff increased from 24.92% to 28.96%[74]. - The company has a diverse compensation policy to attract and retain talent, aligning employee contributions with their compensation[153].